1968-28-1

Usage

Uses

Used in Pharmaceutical Industry:
4H-Imidazol-4-one,3,5-dihydrois used as a key intermediate in the synthesis of various pharmaceuticals for its ability to form complex molecular structures that can target specific biological pathways.
Used in Agrochemical Industry:
In the agrochemical sector, 4H-Imidazol-4-one,3,5-dihydroserves as a crucial component in the development of new pesticides and other crop protection agents, leveraging its chemical properties to enhance crop yield and protection.
Used in Dye Production:
4H-Imidazol-4-one,3,5-dihydrois utilized as a building block in the creation of dyes, contributing to the colorfastness and vibrancy of textiles and other materials.
Used in Organic Synthesis:
As a versatile intermediate, 4H-Imidazol-4-one,3,5-dihydrois employed in organic synthesis for the production of a wide range of organic compounds, showcasing its adaptability in various chemical reactions and processes.

Upstream product

• 114981-07-6 N-formimidoyl-glycine phenethyl ester; hydrochloride 
• 3034-38-6 5-nitro-1H-imidazole 
• 6011-14-9 2-aminoacetonitrile hydrochloride 
• 122-51-0 orthoformic acid triethyl ester 
• 149-73-5 trimethyl orthoformate 
• 88945-41-9 N-(Cyanmethyl)formimidsaeure-methylester 
• 288-32-4 1H-imidazole 

Relevant academic research and scientific papers

Conversion of imidazoles to imidazolones with chloramine-B: kinetic and mechanistic study

Oxidative conversion of 1H-imidazole (IzlH) and 2-substituted imidazoles viz., 2-ethyl-1H-imidazole (2-EtIzlH), 2-methyl-1H-imidazole (2-MeIzlH), 1H-imidazole-2-ester (2-EsIzlH), and 1H-imidazole-2-carbaldehyde (2-CaIzlH) to the corresponding imidazolones with sodium N-chlorobenzenesulfonamide or chloramine-B (CAB) were established. This reaction was kinetically investigated at 303?K in HClO4 medium. Under comparable experimental conditions, the oxidation reactions followed identical kinetics for all the five imidazoles with a first-order dependence of rate on [CAB]o and fractional-order dependence each on [imidazole]o and [H+]. Effects of added benzenesulfonamide, halide ions, NaClO4, and MeOH on the rate of reaction have been studied. Reaction products were identified and characterized by GC–MS and NMR spectral analysis. The rates are measured at different temperatures and the composite activation parameters have been computed from the Arrhenius plots. Isokinetic temperature (β) was found to be 449?K which is higher than the experimental temperature (303?K), indicating that the rate has been under enthalpy control. Relative reactivity of these imidazoles is in the order: 2-EtIzlH?>?2-MeIzlH?>?IzlH?>?2-EsIzlH?>?2-CaIzlH. H2O+Cl have been postulated as the reactive oxidizing species. The reaction mechanism and the derived rate law are in good agreement with the observed experimental results. Spectroscopic studies have been made for an intermediate complex formation between CAB and imidazole. Advantages of the present method include: mild reaction conditions, cost-effectiveness, short reaction time, ease of isolation of products, and the use of eco-friendly reagents. Hence, the methodology developed could be adopted for the facile oxidative conversion of imidazoles to imidazolones and can be scaled up to industrial operation with suitable modification. Graphical abstract: [Figure not available: see fulltext.]

IMIDATES IN ORGANIC SYNTHESIS: METHYL N-CYANOMETHYLMETHANIMIDATE

Synthesis, preliminary properties and reactions of the reagent Methyl N-cyanomethylmethanimidate are reported.

IMIDAZOLE BIARYL COMPOUNDS AS S-NITROSOGLUTATHIONE REDUCTASE INHIBITORS

The present disclosure is directed to compounds of formula (Ie) and pharmaceutically acceptable salts thereof, wherein A, B, R1, R2, m, n, X1, X2, X3 and X4 are as defined herein, which are active as inhibitors of S-Nitrosoglutathione reductase (GSNOR). These compounds prevent, inhibit, or suppress the action of GSNOR and are therefore useful in the treatment of GSNOR mediated diseases, disorders, syndromes or conditions such as, e.g., pulmonary hypertension, acute respiratory distress syndrome (ARDS), asthma, bronchospasm, cough, pneumonia, pulmonary fibrosis, interstitial lung diseases, cystic fibrosis and chronic obstructive pulmonary disease (COPD).

Method of treating or preventing cardiac arrhythmia employing an N-substituted heterocyclic derivative

The invention relates to the use of an N-substituted heterocyclic derivative and its pharmaceutically acceptable salts for the treatment or prevention of cardiac arrhythmia. These derivatives have the structure STR1

Imidazolines N-substituted by a biphenylmethyl group, their medical use and the pharmaceutical compositions therefor

The invention relates to compounds of the formula STR1 in which X and R1 -R5 are defined in the specification and their salts where appropriate, all of which are useful as angiotensin II antagonists.

Dinitrogen heterocyclic derivatives N-substituted by a biphenylmethyl group, and the pharmaceutical compositions in which they are present

This invention relates to compounds of formula STR1 in which: R1 and R2 are similar or different and are each independently hydrogen or a group selected from CO2 N=C(NH2)2, CONHNHCONH2, CONHNHCSNH2, C(OC2 H5)=NCO2 CH3, COCH2 CO2 H5, N(OH)-CONHCOOC2 NCO2 CH3, COCH2 CO2 H5, N(OH)-CONHCOOC2 H5, C(OC2 H5)=NH or a nitrogen heterocycle; with the proviso that at least one of the substituents R1 or R2 is other than hydrogen; R3 is a hydrogen, a C1 -C6 alkyl, a C2 -C6 alkenyl, a C3 -C7 cycloalkyl, a phenyl, a phenylalkyl, or a phenylalkenyl; R4 and R5 are each independently a C1 -C6 alkyl, a C3 -C7 cycloalkyl, a phenyl or a phenylalkyl; or R4 and R5, bonded together, are either a group of the formula (CH2)n or a group of the formula (CH2)p Y (CH2)q, in which Y is either an oxygen atom, or a sulfur atom, or a substituted carbon atom, or a group N-R6, in which R6 is a hydrogen, a C1 -C4 alkyl, a phenylalkyl, a C1 -C4 alkylcarbonyl, a C1 -C4 halogenoalkylcarbonyl, a C1 -C4 polyhalogenoalkylcarbonyl, a benzolyl, an α-aminoacyl or a N-protecting group, or R4 and R5, together with the carbon atom to which they are bonded, form an indane or an adamantine; p+q=m; n is an integer between 2 and 11; m is an integer between 2 and 5; X is an oxygen or a sulfur atom; and z and t are zero or z+t=1; and its salts.

N-SUBSTITUTED HETEROCYCLIC DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS IN WHICH THEY ARE PRESENT

The invention relates to N-substituted heterocyclic derivatives and its salts. These derivatives have the formula (I) in which the substituents are as defined in the specification. Application: Angiotensin II antagonists

N-SUBSTITUTED HETEROCYCLIC DERIVATIVES USEFUL IN THE TREATMENT OF CARDIOVASCULAR DISORDERS

The present invention relates to N-substituted heterocyclic derivatives of formula: STR1 processes for their preparation, and pharmaceutical compositions which contain them. The compounds according to the invention are non-peptide compounds which oppose the action of angiotensin II. The compounds according to the invention are thus useful in the treatment of cardiovascular disorders such as hypertension and heart failure.

Benzenesulfonyl carboxamide compounds useful as herbicidal agents

There are provided novel benzenesulfonyl carboxamide compounds and novel intermediate benzenesulfonyl-2-imidazolin-5-one compounds, novel intermediates and methods for the preparation of said compounds, and a method for controlling a variety of annual and

An Efficient, One-Step Synthesis of 2-Imidazolin-4(5)-one

Die Titelverbindung 4, das lange bekannte biologische Zwischenprodukt beim Abbau von Xanthin zu N-(Iminomethyl)glycin, wird in einer einstufigen Umsetzung von Aminoacetonitril-hydrochlorid mit ueberschuessigem Trimethyl-orthoformat mit einer Ausbeute von mehr als 90percent erhalten.Der Mechanismus der Reaktion wird diskutiert.